Increased cholesterol efflux potential of sera from ApoA-I-Milano carriers and transgenic mice

The ability of HDL to remove cholesterol from peripheral cells and drive it to the liver for excretion is believed to explain most of the strong inverse correlation between plasma HDL cholesterol levels and coronary heart disease. Carriers of the ApoA-I(Milano) (A-I(M)) mutant have a severe hypoalphalipoproteinemia but are not at increased risk for premature of coronary heart disease. To explain this apparent paradox, we compared the capacity of serum from A-I(M) and control subjects to extract cholesterol from Fu5AH cells. Because the A-I(M) carriers are all heterozygotes for the mutation, we also compared the cholesterol efflux capacity of serum from transgenic mice expressing A-I(M) or wild-type ApoA-I (A-I(WT)), in the absence of murine ApoA-I. In the whole series of human or mouse sera, cholesterol efflux was significantly correlated with several HDL-related parameters; after adjustment for concomitant variables, the only parameter that remained significantly correlated with cholesterol efflux was the serum ApoA-I concentration (r2=0.85 in humans and 0.84 in mice). The same was true when samples from control subjects, A-I(M) carriers, A-I(WT) or A-I(M) mice were analyzed separately. Cholesterol efflux to sera from the A-I(M) carriers was only reduced slightly compared with control sera (25.0±4.2% versus 30.4±3.3%), although there was a large reduction (-45%) in the serum ApoA-I concentration in the former. Cholesterol efflux was also lower to sera from A-I(M) than A-I(WT) mice (15.6±3.8% versus 30.1±7.1%), but less than expected from the 70% reduction in serum ApoA-I concentration. A relative efflux potential of serum was calculated in each group as the slope of the regression line fitting cholesterol efflux to ApoA-I concentrations. Therefore, the relative efflux potential reflects the relative efficiency of ApoA-I in determining cell cholesterol efflux. The relative efflux potential of mouse and human sera was in the following order: A-I(M) mice>A-I(M) carriers>A-I(WT) mice=control subjects, suggesting a gene-dosage effect of the A-I(M) mutation on the efficiency of serum to extract cholesterol from cells. The high efficiency of A-I(M)-containing HDL for cell cholesterol uptake would result in an improved reverse cholesterol transport in the A- I(M) carriers, possibly explaining the low susceptibility to atherosclerosis development.